3 results
To assess the feasibility and efficacy of 90Y-ibritumomab tiuxetan consolidation treatment after R-PECC chemotherapy as second or third line treatment in patients with refractory or relapsed aggressive B-cell NHL, after or not eligible for…
In this non-inferiority study, we aim to identify the diagnostic value of indocyanine green (ICG) fluorescence imaging for SLN mapping versus the standard-of-care 99mTc in the SLN procedure for breast cancer patients.
Primary objective• To explore the feasibility of multiple dose administration of oxybutynin via the MedRing OAB system in an outpatient setting.• Safety and tolerability of 28 days of intravaginal dosing of oxybutynin via the MedRingSecondary…